5d 1m 3m 1y 5y 10y
There are 2 articles on this stock available only to PRO subscribers.
There are no Transcripts on NVIV.
Business Wire (Feb 24, 2014)
Business Wire (Jan 3, 2014)
Business Wire (Dec 27, 2013)
InVivo Therapeutics to Move Forward with Its First Clinical Trial After Receiving FDA Conditional ApprovalBusiness Wire (Dec 26, 2013)
Business Wire (Dec 23, 2013)
Business Wire (Dec 16, 2013)
Business Wire (Dec 9, 2013)
NVIV vs. ETF Alternatives
InVivo Therapeutics Corporation is developing and intends to commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI). InVivo intends to leverage itsplatform technology to deliver three products to the market.